Borregaard First Quarter 2024 Earnings: EPS Misses Expectations
Borregaard (OB:BRG) First Quarter 2024 Results
Key Financial Results
- Revenue: kr1.98b (up 6.8% from 1Q 2023).
- Net income: kr200.0m (down 13% from 1Q 2023).
- Profit margin: 10% (down from 13% in 1Q 2023). The decrease in margin was driven by higher expenses.
- EPS: kr2.01 (down from kr2.32 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Borregaard EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.2%.
Looking ahead, revenue is forecast to grow 3.0% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Chemicals industry in Norway.
Performance of the Norwegian Chemicals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Borregaard that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Borregaard might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OB:BRG
Borregaard
Engages in the development, production, and marketing of specialized biomaterials and biochemicals in Norway, rest of Europe, the United States, Asia, and internationally.
Flawless balance sheet with reasonable growth potential and pays a dividend.